- ProMIS Neurosciences (PMN) to present at the American Academy of Neurology 2023 annual meeting (AAN)
- ProMIS is a biotechnology company working on the next generation and development of antibody therapeutics for Alzheimer’s disease and more
- Taking place from April 22 to 27.
- The presentation will focus on next-generation neurodegenerative disease therapeutics
- Also discussed will be data about lead drug AD candidate PMN310
- ProMIS Neurosciences is trading at C$6.35 at 11:02 am EST
ProMIS Neurosciences (PMN) will be presenting at the upcoming American Academy of Neurology (AAN) annual meeting in Boston, Massachusetts.
ProMIS is a biotechnology company working on the next generation and development of antibody therapeutics for Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA).
Presentation
Taking place from April 22 to 27. The presentation will focus on next-generation neurodegenerative disease therapeutics.
Titled: Rational Design of a Vaccine for Alzheimer’s Disease Using Computationally-Derived Conformational B Cell Epitopes to Selectively Target Toxic Amyloid-Beta Oligomers. Dr. Johanne Kaplan will be leading the discussion.
Up for discussion
Also discussed will be data that further characterize lead drug AD candidate PMN310, as well as preclinical optimization studies of an Alzheimer’s vaccine and data supporting RACK1 as a potential target in amyotrophic lateral sclerosis (ALS).
ProMIS Neurosciences is a development-stage biotechnology company, down 1.55 per cent, trading at C$6.35 at 11:02 am EST.
